title: P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage.
abstract: Transgenic rats overexpressing both human renin and angiotensinogen genes (dTGR) develop hypertension, inflammation, and renal failure. We tested the hypothesis that these pathological features are associated with changes in renal P450-dependent arachidonic acid (AA) metabolism. Samples were prepared from 5- and 7-week-old dTGR and from normotensive Sprague-Dawley (SD) rats, ie, before and after the dTGR developed severe hypertension and albuminuria. At both stages, dTGR showed significantly lower renal microsomal AA epoxygenase and hydroxylase activities that reached 63% and 76% of the control values at week 7. Furthermore, the protein levels of several potential AA epoxygenases (CYP2C11, CYP2C23, and CYP2J) were significantly reduced. Immunoinhibition studies identified CYP2C23 as the major AA epoxygenase, both in dTGR and SD rats. Immunohistochemistry showed that CYP2C23 was localized in cortical and outer medullary tubules that progressively lost this enzyme from week 5 to week 7 in dTGR. CYP2C11 expression occurred only in the outer medullary tubules and was markedly reduced in dTGR compared with age-matched SD rats. These findings indicate site-specific decreases in the availability of AA epoxygenase products in the kidney of dTGR. In contrast to renal microsomes, liver microsomes of dTGR and SD rats showed no change in the expression and activity of AA epoxygenases and hydroxylases. We conclude that hypertension and end-organ damage in dTGR is associated with kidney-specific downregulation of P450-dependent AA metabolism. Because the products of AA epoxygenation have anti-inflammatory properties, this alteration may contribute to uncontrolled renal inflammation, which is a major cause of renal damage in dTGR.
authors.affiliation: Max Delbrück Center for Molecular Medicine and Franz Volhard Clinic, HELIOS Kliniken-Berlin, Medical Faculty of the Charité, Humboldt University of Berlin, Germany.
authors.forename: Eva
authors.initials: E
authors.lastname: Kaergel
authors.forename: Dominik N
authors.initials: DN
authors.lastname: Muller
authors.forename: Horst
authors.initials: H
authors.lastname: Honeck
authors.forename: Juergen
authors.initials: J
authors.lastname: Theuer
authors.forename: Erdenechimeg
authors.initials: E
authors.lastname: Shagdarsuren
authors.forename: Alexander
authors.initials: A
authors.lastname: Mullally
authors.forename: Friedrich C
authors.initials: FC
authors.lastname: Luft
authors.forename: Wolf-Hagen
authors.initials: WH
authors.lastname: Schunck
mesh_terms: D000804:Angiotensin II / Q000502:physiology; D000808:Angiotensinogen / Q000235:genetics; D000818:Animals; D030801:Animals, Genetically Modified; D016718:Arachidonic Acid / Q000378:metabolism*; D001189:Aryl Hydrocarbon Hydroxylases; D000090762:Cytochrome P-450 CYP2J2; D003577:Cytochrome P-450 Enzyme System / Q000032:analysis / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D000072467:Cytochrome P450 Family 2; D006977:Hypertension, Renal / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology*; D007668:Kidney / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D007700:Kinetics; D010105:Oxygenases / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D051437:Renal Insufficiency / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology*; D012083:Renin / Q000235:genetics; D012084:Renin-Angiotensin System; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000032:analysis / Q000378:metabolism
chemical_list: C000717351:Cyp2c23 protein, rat; D000808:Angiotensinogen; D000804:Angiotensin II; D016718:Arachidonic Acid; D003577:Cytochrome P-450 Enzyme System; D010105:Oxygenases; D013250:Steroid Hydroxylases; D001189:Aryl Hydrocarbon Hydroxylases; C450279:CYP2C11 protein, rat; D000090762:Cytochrome P-450 CYP2J2; D000072467:Cytochrome P450 Family 2; D039181:Steroid 16-alpha-Hydroxylase; D012083:Renin